Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MultiTAA-specific T cells (Baylor College of Medicine)
- Development stage
- Unknown
- Lead developer
- Marker Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MultiTAA-specific T cells (Baylor College of Medicine) is an investigational, non-genetically modified cell-based immunotherapy developed for the treatment of acute lymphoblastic leukemia (ALL), particularly in the post-allogeneic hematopoietic stem cell transplant (HSCT) setting. Developed by Baylor College of Medicine in partnership with Marker Therapeutics, the therapy utilizes T cells derived from the patient's stem cell donor. These T cells are expanded and trained ex vivo to recognize three specific tumor-associated antigens (TAAs): Wilms Tumor 1 (WT1), Preferentially Expressed Antigen in Melanoma (PRAME), and Survivin, which are frequently overexpressed on ALL cells. Unlike CAR-T therapies, this approach leverages the natural T-cell receptors to provide a multi-targeted immune response, intended to identify and eliminate residual leukemia cells and prevent disease relapse. The therapy is currently being evaluated in the Phase 1 STELLA clinical trial.
- Other names
- Donor-derived multiTAA-specific T cellsMulti-tumor-associated antigen-specific T cellsMultiTAA-specific T cells
02
Targets
pMHC-I (Peptide–MHC class I complex)Synovial sarcoma X breakpoint 2-derived peptide-human leukocyte antigen complexesSurvivin-peptide-HLA (Survivin/BIRC5-derived peptide-HLA complexes)PRAME peptide–HLA complexNY-ESO-1-pHLA (New York esophageal squamous cell carcinoma 1-derived peptide-human leukocyte antigen complex (NY-ESO-1-derived peptide-HLA complex))MAGE-A4-pMHC (Melanoma-associated antigen A4-derived peptide-human leukocyte antigen complex)
Beyond the preview
Go deeper on MultiTAA-specific T cells (Baylor College of Medicine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MultiTAA-specific T cells (Baylor College of Medicine).